Navigation Links
Halt Medical, Inc. Receives FDA Clearance
Date:6/15/2010

LIVERMORE, Calif., June 15 /PRNewswire/ -- Halt Medical, Inc., today announced that the U.S. Food and Drug Administration (FDA) has cleared the Halt 2000GI™ Electrosurgical System for soft tissue ablation using radiofrequency energy.  "This clearance to market is a major milestone for our customers, employees and investors," said Russ DeLonzor, President and Chief Operating Officer. 

Radiofrequency Ablation (RFA) with the Halt System is a very precise, minimally invasive procedure where a slender probe is inserted into the target tumor under ultrasound guidance.  Once in position, the system delivers a specified amount of energy to the tissue.  The heat generated in the process destroys the tumor, allowing it to be absorbed by the body.  RFA therapy is rapidly becoming the treatment of choice among surgeons seeking minimally invasive solutions for relieving debilitating symptoms caused by a variety of diseases such as tumors of the liver, breast, prostate, bone, and kidneys.   

"The Halt System offers broad advantages over surgery to doctors, their patients, and the healthcare system," according to Gordon Epstein, MD, Chief Technology Officer.  "With traditional surgical interventions, layers of healthy tissue are cut through to gain access to the tumor.  This leads to complications, significant pain, and long recovery times.  With RFA, patients typically go home the same day and are back to work much sooner.  The direct and indirect savings to the healthcare system as we replace radical surgery with minimally invasive procedures like Halt RFA will be in the billions of dollars."   

Halt Medical was founded in 2005 by Jeffrey M. Cohen, Dr. Bruce B. Lee, and Ed Calesa with the goal of developing an RFA system optimized for the treatment of symptomatic uterine fibroids.  The Halt Fibroid System was recently approved for use in Europe, and is currently being studied for this indication in the U.S.  "Receiving clearance by the FDA to market our general use ablation system represents a significant step towards our goal of extending the benefits of RFA to the treatment of uterine fibroids in the U.S.," said Mr. Cohen. 

Information about the Halt Fibroid Study and a list of clinical sites in the U.S. may be found at www.clinicaltrials.gov, study number NCT00874029.


'/>"/>
SOURCE Halt Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Apnex Medical, Inc. Names Chas McKhann President, Chief Executive Officer
2. Binder Biomedical, Inc. Announces the Release of the X-GRAFT(TM) Interspinous Device, as Part of Their QUANTUM(TM) Line of Spinal Allograft Devices, Manufactured at the University of Miami Tissue Bank
3. TriReme Medical, Inc. Receives FDA 510K Clearance for Glider(TM) PTA Balloon Catheter
4. Chinas leading electronic systems design event to highlight next-generation medical, automotive and green power technologies
5. Solta Medical, Inc. Announces Fourth Quarter 2009 Results Release Date and Conference Call
6. Tenaxis Medical, Inc. Announces Completion of the Enrollment Phase of Their Pivotal Study
7. China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters
8. China Sky One Medical, Inc.s AMI Diagnostic Kit Recognized as a National Innovation Project by NDRC
9. Home Care of the Carolinas and Alliance Medical, Inc. Select Authentidates Inscrybe Healthcare to Improve Care Order Processing
10. Apnex Medical, Inc. Raises Additional $14 Million
11. China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)...  Eli Lilly and Company (NYSE: LLY ) ... resolve pending patent litigation in the U.S. District Court for ... the Cialis ® (tadalafil) unit dose patent. This patent ... part of the agreement, Cialis exclusivity is now expected to ... "The unit dose patent for Cialis is valid and infringed ...
(Date:7/11/2017)... , July 11, 2017  Sysmex America, Inc., ... diagnostic testing equipment as well as middleware information ... way to make quality assurance easier and more ... is well known for the innovation that it ... Monitor elevates quality assurance processes to a new ...
(Date:7/10/2017)... , July 10, 2017 The Institute for ... methods, is the recipient of a VITROCELL® inhalation exposure ... International Science Consortium. The device, which is designed to ... expose human lung cells to airborne test materials in ... use the VITROCELL® system for testing combustible tobacco products, ...
Breaking Medicine Technology:
(Date:7/24/2017)... PARK (PRWEB) , ... July 24, 2017 , ... Engineers ... is bio-compatible, because it produces the same kind of electrical energy that the body ... the form of moving electrons. This flow of electrons out of the battery is ...
(Date:7/24/2017)... ... , ... Cheerag D. Upadhyaya , M.D., M.Sc., FAANS has been appointed ... part of Saint Luke’s Health System . Dr. Upadhyaya has served in the ... FAANS joins Stanley P. Fisher, M.D., who has served as medical co-director ...
(Date:7/24/2017)... , ... July 24, 2017 , ... Cosmetic Town, an ... and the cosmetic surgeries they perform on a daily basis. , The new ... surgery procedures they specialize in at their practices. , When asked about the ...
(Date:7/24/2017)... ... 2017 , ... Horizon Goodwill Industries, SourceAmerica and ... high school girls succeed in STEM programs as well as help Horizon Goodwill ... over 20 high school girls at their corporate headquarters on Tuesday, July 25, ...
(Date:7/24/2017)... ... July 24, 2017 , ... Peruvian ... awards to be awarded annually to and divided between two full-time university students ... awareness to Amazonian plant medicine. To apply for the scholarship, students are asked ...
Breaking Medicine News(10 mins):